Capricor Therapeutics(US:CAPR) Globenewswire·2025-03-11 13:00Core Viewpoint - Capricor Therapeutics is set to release its financial results for Q4 and the full year of 2024 on March 19, 2025, followed by a conference call to discuss the results and recent corporate updates [1][2]. Company Overview - Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapeutics aimed at treating rare diseases [3]. - The company's lead product candidate, deramiocel, is an allogeneic cardiac-derived cell therapy currently in late-stage development for Duchenne muscular dystrophy [3]. - Capricor is also utilizing its proprietary StealthX™ platform for exosome technology in preclinical development, targeting areas such as vaccinology and targeted delivery of therapeutics [3]. Conference Call Details - The conference call will take place on March 19, 2025, at 4:30 p.m. ET, with toll-free and international dial-in options provided for participants [2]. - A replay of the webcast will be available on the company's website after the live broadcast [2]. Recent Developments - Capricor has entered into an exclusive commercialization and distribution agreement for deramiocel in the U.S. and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [6].